Komori, Mika
Ozeki, Akichika
Tanji, Yuka
Kamiki, Eriko
Krege, John H.
Li, Lily Qian
Suzuki, Shiho
Shibata, Mamoru
Takeshima, Takao
Funding for this research was provided by:
Eli Lilly Japan K.K.
Daiichi Sankyo Company, Limited
Eli Lilly and Company
Article History
Received: 19 December 2023
Accepted: 5 March 2024
First Online: 25 March 2024
Declarations
:
: The study was carried out in accordance with the protocol, applicable local laws and regulations, and consensus principles derived from the International Conference on Harmonisation Good Clinical Practice guidelines, Declaration of Helsinki, and Council for International Organizations of Medical Sciences International Ethical Guidelines. The study protocol was approved by ethical review boards at each study site (full list previously published in Tassorelli et al., 2021 [CitationRef removed]). Written informed consent was obtained from all patients prior to enrollment.
: Not applicable.
: All authors declare that medical writing and article processing costs were provided by Eli Lilly Japan K.K. and Daiichi Sankyo Company, Ltd.SS declares honoraria from Amgen K.K., Daiichi Sankyo Company Ltd, Eli Lilly Japan K.K., and Otsuka Pharmaceutical Co. Ltd.MS declares honoraria from Amgen Astellas BioPharma K.K., Daiichi Sankyo Company Ltd, Eli Lilly Japan K.K., and Otsuka Pharmaceutical Co. Ltd.TT declares research funding and collaborative research expenses from Biohaven, Ltd., Eisai Co., Eli Lilly Japan K.K., Ltd, Lundbeck Japan K.K., and Shionogi and Co., Ltd; honoraria from Amgen Astellas BioPharma K.K., Daiichi Sankyo Company Ltd, Eli Lilly Japan K.K., and Otsuka Pharmaceutical Co. Ltd; and advisory roles for Hedgehog MedTech, Inc., Sawai Pharmaceutical Co., Ltd.JHK and LQL are employees and minor shareholders of Eli Lilly and Company.MK, AO, YT, and EK are employees of Eli Lilly Japan and minor shareholders of Eli Lilly and Company.